Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ. Wedge SR, et al. Among authors: smith nr. Cancer Res. 2005 May 15;65(10):4389-400. doi: 10.1158/0008-5472.CAN-04-4409. Cancer Res. 2005. PMID: 15899831
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
Brave SR, Odedra R, James NH, Smith NR, Marshall GB, Acheson KL, Baker D, Howard Z, Jackson L, Ratcliffe K, Wainwright A, Lovick SC, Hickinson DM, Wilkinson RW, Barry ST, Speake G, Ryan AJ. Brave SR, et al. Among authors: smith nr. Int J Oncol. 2011 Jul;39(1):271-8. doi: 10.3892/ijo.2011.1022. Epub 2011 Apr 29. Int J Oncol. 2011. PMID: 21537841
Tumor stromal phenotypes define VEGF sensitivity--response.
Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X, Mistry S, McDaid K, Kendrew J, Womack C, Wedge SR, Barry ST. Smith NR, et al. Clin Cancer Res. 2014 Oct 1;20(19):5141. doi: 10.1158/1078-0432.CCR-14-0681. Clin Cancer Res. 2014. PMID: 25274380 No abstract available.
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer.
Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, Kayani I, Bex A, Wan E, O'Mahony FC, O'Donnell M, Chowdhury S, Doshi R, Ho-Yen C, Gerlinger M, Baker D, Smith N, Davies B, Sahdev A, Boleti E, De Meyer T, Van Criekinge W, Beltran L, Lu YJ, Harrison DJ, Reynolds AR, Powles T. Sharpe K, et al. Clin Cancer Res. 2013 Dec 15;19(24):6924-34. doi: 10.1158/1078-0432.CCR-13-1631. Epub 2013 Oct 15. Clin Cancer Res. 2013. PMID: 24130073 Clinical Trial.
166 results